Lipoprotein(a): What's in a measure?

Annals of Clinical Biochemistry

Volumn 37, Issue 5, 2000, Pages 571-580

  Wieringa, G ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; LIPOPROTEIN A;

AGE; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNORADIOMETRIC ASSAY; KIDNEY DISEASE; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RACE DIFFERENCE; REVIEW;

EID: 0033822662     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563001899799     Document Type: Review

References (55)

1. A new serum type system in man - The Lp system
2. Radio-immunoassay of human plasma Lp(a) lipoprotein
3. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia
4. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum Lp(a) levels
5. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population of middle-aged men
6. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
7. Quantitative genetic studies of the human plasma Lp(a) lipoprotein
8. Lipoprotein Lp(a) and the risk of myocardial infarction
9. The mysteries of lipoprotein(a)
10. Lipoprotein(a): Structure, measurement, and clinical significance
11. Immunochemical quantification of human plasma Lp(a) lipoprotein
12. Quantitation, isolation and characterisation of human lipoprotein(a)
13. Lipoprotein(a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies
14. Enzyme-linked immunoassay for Lp(a)
15. Automated measurement of Lp(a) by immunoturbidimetric analysis
16. The determination of lipoprotein Lp(a) by rate and end point nephelometry
17. Characterisation of five mouse monoclonal antibodies to apolipoprotein(a) from human plasma Lp[a]: Evidence for weak plasminogen reactivity
18. The unique lipoprotein(a): Properties and immunochemical measurement
19. Micromethod for immunochemical quantitation of dextran and studies on the role of antigen size in single radial immunodiffusion
20. Quantification of lipoprotein(a) particles containing various apolipopotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal antiapolipoprotein B detection antibody sandwich enzyme immunoassay
21. Evaluation of a new automated latex agglutination assay for lipoprotein(a): A comparison with a manual ELISA
22. Measurement of lipoprotein(a): Comparison of Macra and Immubind methods
23. A comparison of commercial kits for the measurement of lipoprotein(a)
24. Determination of lipoprotein(a): Evaluation of three methods
25. Comparison of lipoprotein(a) assay methods in serum and plasminogen-free fraction
26. Report on the Lp(a) workshop-Manchester, June 1991. The Multi-centre Lipoprotein(a) Method Study Group
27. International Lp(a) standardisation
28. Lipoprotein(a): Biology, clinical utility and measurement
29. Standardisation of Lp(a) measurements
30. Effect of number of apolipoprotein(a) kringle 4 domains on immunochemical measurement of lipoprotein(a)
31. Standardisation of Lp(a) measurements
32. Lipoprotein(a) concentrations and apolipoprotein(a) phenotype in Caucasians and African Americans: The CARDIA study
33. The relationship between infant and parent Lp(a) concentrations
34. Lipoprotein(a) in PROCAM participants and young myocardial infarction survivors
35. Increased serum lipoprotein(a) in diabetes mellitus and their reduction with glycaemic control
36. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study Cohort
37. Lipoprotein(a) patients with proteinuria
38. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis
39. A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles
40. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction
41. Acute and long-term changes in serum lipids after acute stroke
42. Time course of serum Lp(a) in men after coronary artery bypass grafting
43. Transient changes of serum lipoprotein(a) as an acute phase protein
44. Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment
45. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
46. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment of patients with isolated GH deficiency
47. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient adults
48. Effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone deficient adults
49. Growth hormone replacement can reduce serum Lp(a) concentration
50. Lipoprotein(a) changes during growth hormone treatment
51. Method-dependent increase in lipoprotein(a) in insulin-dependent diabetes mellitus during pregnancy
52. Changes in Lp(a) concentration during exercise are assay dependent
53. Lipoprotein(a) changes during and after coronary artery bifurcation grafting: An epiphenomenon?
54. Lipoprotein(a), a clinically elusive lipoprotein particle
55. International Federation of Clinical Chemistry standardisation project for the measurement of lipoprotein(a). Phase 1. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators